•  
  •  
 

Article Type

Original Study

Abstract

Objectives The aim of this work was to study the efficacy of hyoscine butylbromide (HBB) for shortening of the first stage of labor in primigravid women. Background Prolonged labor is one of the most important risk factors for perinatal compromise and, if caused by obstructed labor, it carries the risk for uterine rupture, postpartum hemorrhage, puerperal sepsis, and maternal death. Patients and methods The study was a randomized, double-blinded, controlled trial. One hundred and ten primigravid term pregnant women in spontaneous labor received either HBB or a placebo intramuscularly once the women entered the active phase of labor. The primary outcome measured was the duration of the first stage of labor. Secondary outcomes were the duration of the second and third stages of labor, blood loss at delivery, rate of cesarean section, and Apgar scores for the neonates. Results A total of 110 women yielded data for analysis. Of them, 55 women received HBB and 55 received placebo. The mean duration of the first stage in the study group was 208.16 ± 17.24 min, compared with 258.16 ± 15.27 min in the control group; there was a highly significant statistical difference (P = 0.00). There were no significant changes in the duration of the second stages of labor (P = 0.09). There were no significant changes in the duration of the third stages of labor (P = 0.16). There were no significant statistical differences in blood loss or Apgar scores. There was no significant statistical difference in the cesarean section rate or instrumental delivery. Conclusion HBB is effective in significantly reducing the duration of the first stage of labor and is not associated with any apparent short-term adverse outcomes in the mother or neonate.

Download

Share

COinS